IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.

doi:10.1158/1078-0432.CCR-09-2902

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Mar 2010

van den Bent Martin J, Dubbink Hendrikus J, Marie Yannick, Brandes Alba A, Taphoorn Martin J B, Wesseling Pieter, Frenay Marc, Tijssen Cees C, Lacombe Denis, Idbaih Ahmed, van Marion Ronald, Kros Johan M, Dinjens Winand N M, Gorlia Thierry, Sanson Marc

Abstract excerpt

PURPOSE: Recent studies have shown the prognostic significance of IDH1 mutations in glioma. It is yet unclear if IDH1 mutations are predictive for outcome to chemotherapy. We determined the effect of IDH1 mutations on progression-free survival and overall survival (OS), and its correlation with other clinical and molecular features in the prospective randomized European Organization for Research and Treatment of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Modification Methylases

Share to DNA Repair Enzymes

Share to Genes, erbB-1

Share to Isocitrate Dehydrogenase

Share to Oligodendroglioma

Share to Radiotherapy

Share to Vincristine

Source

Open in PubMed

Identifiers

PMID: 20160062
DOI: 10.1158/1078-0432.CCR-09-2902

Genes

IDH1
MGMT
IDH2
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.PMID 20160062Read ↗

Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.Semantic proximity Read ↗

Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.Semantic proximity Read ↗

IDH mutations: genotype-phenotype correlation and prognostic impact.Semantic proximity Read ↗

Perspectives of Personalized Chemotherapy of Gliomas Based on Molecular Tumor Profiling.Semantic proximity Read ↗

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.Semantic proximity Read ↗

Prognostic or predictive value of <i>MGMT</i> promoter methylation in gliomas depends on <i>IDH1</i> mutationSemantic proximity Read ↗

Molecular markers in low-grade gliomas: predictive or prognostic?Semantic proximity Read ↗

Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups.Semantic proximity Read ↗

Unlocking new horizons: advances in treating IDH-mutant, 1p/19q-codeleted oligodendrogliomasSemantic proximity Read ↗

Predictive and prognostic factors for gliomas.Semantic proximity Read ↗

Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution.Semantic proximity Read ↗

Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.